Ceryvyn Therapeutics Ltd
OPT
株式のランク
#31877
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
株価
$0.00846342
最終同期: 2026-07-27
時価総額
$11.27M
変化（1日）
0.00%
変化（1年）
-99.75%
国
AU
取引 Ceryvyn Therapeutics Ltd (OPT)
カテゴリー
Healthcare
Ceryvyn Therapeutics Ltd（OPT）のEPS
June 2025 時点のEPS TTM: $-1.84
Ceryvyn Therapeutics Ltdの最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-1.84です。2024年末には、EPSは$-22.16で、2023年のEPS$-3.60と減少でした。
Ceryvyn Therapeutics LtdのEPS履歴（2000から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-1.84 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | $-22.16 | 515.56% |
| 2023 | $-3.60 | 32.35% |
| 2022 | $-2.72 | 88.89% |
| 2021 | $-1.44 | 317.39% |
| 2020 | $-0.35 | -31.78% |
| 2019 | $-0.51 | 17.71% |
| 2018 | $-0.43 | 106.64% |
| 2017 | $-0.21 | -6.98% |
| 2016 | $-0.22 | 3.66% |
| 2015 | $-0.22 | -59.90% |
| 2014 | $-0.54 | -17.14% |
| 2013 | $-0.65 | -18.62% |
| 2012 | $-0.80 | -57.76% |
| 2011 | $-1.89 | 132.13% |
| 2010 | $-0.81 | -26.12% |
| 2009 | $-1.10 | 503.62% |
| 2008 | $-0.18 | -113.42% |
| 2007 | $1.36 | -307.90% |
| 2006 | $-0.65 | -130.68% |
| 2005 | $2.13 | 344.53% |
| 2004 | $0.48 | -270.17% |
| 2003 | $-0.28 | -13.83% |
| 2002 | $-0.33 | 328.31% |
| 2001 | $-0.08 | -179.65% |
| 2000 | $0.10 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -1,041.30% |
US
|
|
| $-7.98 | 333.70% |
US
|
|
| $-5.29 | 187.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,607.61% |
NL
|
